Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Assistive Reproductive Technology Market - Insights
Assisted reproductive technology (ART) are the medical procedures used for infertility treatment, in which eggs are surgically removed from the ovaries and are combined with the sperms in a laboratory. These eggs are then mixed with sperms to form embryos. ART procedure sometimes uses donor eggs, donor sperm, or previously frozen embryos. It may involve a surrogate or gestational carrier.
Rising prevalence and incidence of infertility is expected to drive global assistive reproductive technology market growth in the forecast period
Rising prevalence of infertility has led to an increase in demand for fertility treatments such as In Vitro Fertilization (IVF), Artificial Insemination-Intrauterine Insemination (AI-IUI) and others. In the U.S. prevalence of infertility is rising rapidly. For instance, according to the U.S. Department of Health & Human Services, in 2016, around 10 in 100 (6.1 million) women faced difficulty in getting pregnant.
In past few years there has been significant preference for assistive reproductive technology owing to rising prevalence and incidence of infertility in men and women. For instance, according to the University of Pittsburgh Medical Center (UPMC Pinnacle), around seven million men and women opted for assisted fertility treatments such as IVF in 2015. Moreover, according to the Society for Assisted Reproductive Technology, in 2013, around 175,000 cycles of IVF were conducted, which was a 6% increase compared to 2012.
Such rising prevalence and incidence of infertility had led to an increase in number of assistive reproductive technology (ART) clinics in the U.S. According to the National Centers for Chronic Disease Prevention and Health Promotion, there are total 499 ART clinics in U.S, among which, 464 clinics had reported the ART related data, and in 2015 total 231,936 ART cycles are performed in U.S.
Increasing demand of assistive reproductive technology, has increased the participation of manufacturers in the development of assistive reproductive technology products
Market players are focused on expanding their portfolio of reproductive and fertility treatment products. For instance, Cooper Surgical Inc., a provider of fertility & genomic solutions, has an extensive portfolio ART management systems, IVF workstations, pipettes and needles for sperm or eggs transfer, catheters for embryos transfer, culture media and test kits. Moreover, Hamilton Thorne, In., also provides products such as sperm analyzers and a broad range of ART micropipettes.
FUJIFILM Irvine Scientific, Inc. provides water for assisted reproductive technology use, and also provides various products required for ART procedures. Moreover, Gonagen Medikal also offers various assistive reproductive technology such as IVF, ICSI and others, for infertility treatment.
Companies are also adopting strategies to increase their share in the global assistive reproductive technology market and improve their product portfolio. For instance, in June 2018, Vitrolife AB and GE Healthcare partnered to improve their assisted reproductive technology offerings in the market.
Manufacturers are also engaged in creating awareness regarding In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ISCI) which are expected to propel the global assistive reproductive technology market growth
Manufactures are taking several initiatives for creating awareness and providing training regarding ART technology. For instance, in June 2019 Cooper Surgical Inc. Conducted a workshop in India, to provide complete insight about the pre-requisites and techniques associated with ART, this workshop included lectures, demonstration, and hands-on work training of ART technologies. Moreover, in March 2019 Cooper Surgical Inc., conducted a workshop in Denmark on sperm selection techniques for ICSI procedures.
Global assistive reproductive technology market size was valued at US$ 23,669.2 Mn in 2018, and is expected to witness a CAGR of 5.3% during the forecast period (2019–2027).
Figure 1. Global Assistive Reproductive Technology Market Share (%), By End User, 2019-2027
Source: Coherent Market Insights Analysis (2019)
North America is expected to hold dominant position in global assistive reproductive technology market, due to increasing awareness about fertility treatments, and rising number of hospitals, and ART procedures. For instance, in U.S. 2015 according to National Center For Chronic Disease Prevention and Health Promotion, approximately 38.1% of ART procedures were carried out for age group <35 yrs., and 21.0 % procedures are performed for people in the age group of 35 to 37 years. Such increasing demand for ART procedures is expected to drive the global assistive reproductive technology market growth.
Furthermore, Europe is expected to witness considerable growth in the global assistive reproductive technology market due to increasing number of ART cycles. For instance, in 2014 according to the European society of Human Reproduction and Embryology (ESHRE), around 800,000 treatment cycles were performed from 39 countries in Europe.
Figure 2. Global Assistive Reproductive Technology Market Share (%) Analysis, By Region, 2019 and 2027
Source: Coherent Market Insights Analysis (2019)
Factors restraining the global assistive reproductive technology market growth are availability of alternative treatment such as hormone therapy including hormone injections and tablets such as Choragon, Gonapeptyl, Lutinus, Propess and others.
Key players operating in the global assistive reproductive technology market include Cooper Surgical Inc., Hamilton Thorne, Inc., FUJIFILM Irvine Scientific, Inc., Merck KGaA, Nidacon International AB, Vitrolife AB, EMD Serono, Inc., INVO Bioscience, IVFtech ApS, Gonagen Medikal, Cook Medical LLC., and CellCura ASA.